tradingkey.logo

Sol Gel Technologies Ltd

SLGL
65.780USD
+1.080+1.67%
終値 02/06, 16:00ET15分遅れの株価
183.25M時価総額
損失額直近12ヶ月PER

Sol Gel Technologies Ltd

65.780
+1.080+1.67%

詳細情報 Sol Gel Technologies Ltd 企業名

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltdの企業情報

企業コードSLGL
会社名Sol Gel Technologies Ltd
上場日Feb 01, 2018
最高経営責任者「CEO」- -
従業員数34
証券種類Ordinary Share
決算期末Feb 01
本社所在地Golda Meir 7
都市NESS-ZIONA
証券取引所NASDAQ OMX - NASDAQ BASIC
Israel
郵便番号- -
電話番号97289313433
ウェブサイトhttp://www.sol-gel.com
企業コードSLGL
上場日Feb 01, 2018
最高経営責任者「CEO」- -

Sol Gel Technologies Ltdの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--

収益内訳

会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Fri, Feb 6
更新時刻: Fri, Feb 6
株主統計
種類
株主統計
株主統計
比率
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
他の
7.75%
株主統計
株主統計
比率
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
他の
7.75%
種類
株主統計
比率
Corporation
64.86%
Hedge Fund
13.78%
Investment Advisor
8.54%
Individual Investor
5.14%
Insurance Company
0.27%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.05%
他の
7.20%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
35
617.10K
22.15%
-504.63K
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
383.58K
13.77%
+10.43K
+2.80%
Dec 17, 2025
Phoenix Investment and Finances Ltd
218.22K
7.83%
-28.80K
-11.66%
Sep 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
+7.61K
--
Sep 30, 2025
Morgan Stanley & Co. LLC
4.37K
0.16%
-970.00
-18.18%
Sep 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
--
--
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
比率0%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
May 01, 2025
Merger
10→1
日付
配当落ち日
種類
比率
May 01, 2025
Merger
10→1
KeyAI